Sandrine Aspeslagh

Sandrine Aspeslagh

UNVERIFIED PROFILE

Are you Sandrine Aspeslagh?   Register this Author

Register author
Sandrine Aspeslagh

Sandrine Aspeslagh

Publications by authors named "Sandrine Aspeslagh"

Are you Sandrine Aspeslagh?   Register this Author

47Publications

1852Reads

8Profile Views

Treatment duration of checkpoint inhibitors for NSCLC.

Lancet Respir Med 2019 Oct 7;7(10):835-837. Epub 2019 Aug 7.

Gustave Roussy, Department of Cancer Medicine, 94805 Villejuif, France; Université Paris-Saclay, Orsay, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30192-4DOI Listing
October 2019

Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

J Thorac Oncol 2019 Oct 13;14(10):1701-1703. Epub 2019 Aug 13.

Gustave Roussy, Department of Cancer Medicine, Villejuif, France; Université Paris-Saclay, Orsay, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.07.004DOI Listing
October 2019

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Curr Opin Oncol 2019 Sep;31(5):420-423

Department of Oncology Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000563DOI Listing
September 2019

Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.

Acta Clin Belg 2019 Sep 7:1-5. Epub 2019 Sep 7.

Department of Medical Oncology, Institut Jules Bordet - ULB , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17843286.2019.1664051DOI Listing
September 2019

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.

Nat Rev Clin Oncol 2019 Sep 30. Epub 2019 Sep 30.

ATIP-Avenir Group, UMR981, INSERM (French National Institute of Health and Medical Research), Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0267-4DOI Listing
September 2019

Cancer immunotherapy-associated hypophysitis.

Semin Oncol 2018 06 21;45(3):181-186. Epub 2018 Oct 21.

Department of Radiology, University Hospital of Cagliari, Cagliari, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754183010
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2018.09.002DOI Listing
June 2018

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Ann Rheum Dis 2018 03 27;77(3):468-470. Epub 2017 Feb 27.

Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, Le Kremlin-Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2016-210820DOI Listing
March 2018

Are phase I trials safe for older patients?

J Geriatr Oncol 2018 03 8;9(2):87-92. Epub 2017 Sep 8.

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif Cedex F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.08.012DOI Listing
March 2018

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Eur J Cancer 2018 03 10;91:21-29. Epub 2018 Jan 10.

Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, F-94275, Le Kremlin-Bicêtre, France; INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276, Le Kremlin-Bicêtre, France; Université Paris Sud, UMR 1184, F-94276, Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265, Fontenay-aux-Roses, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.008DOI Listing
March 2018

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Eur J Cancer 2017 12 7;87:65-74. Epub 2017 Nov 7.

Gustave Roussy, Département D'Innovation Thérapeutique et Essais Précoces, Villejuif, France; INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.027DOI Listing
December 2017

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Eur J Cancer 2017 11 9;85:67-77. Epub 2017 Sep 9.

Département des Innovations Thérapeutiques et des Essais Précoces, Gustave Roussy, 114 Rue Edouard-Vaillant, F-94805 Villejuif, France; Département d'Oncologie Médicale, Institut Jules Bordet, rue Héger Bordet 1, B-1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.08.014DOI Listing
November 2017

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Eur J Cancer 2017 10 18;84:202-211. Epub 2017 Aug 18.

Drug Development Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.033DOI Listing
October 2017

TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

Head Neck Pathol 2017 Sep 28;11(3):354-363. Epub 2016 Dec 28.

Department of Pathology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12105-016-0776-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550394PMC
September 2017

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Eur J Cancer 2017 09 22;83:185-193. Epub 2017 Jul 22.

Drug Development Department (DITEP), Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.016DOI Listing
September 2017

Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.

Oral Oncol 2017 07 19;70:34-42. Epub 2017 May 19.

Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2017.05.002DOI Listing
July 2017

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Cancer Chemother Pharmacol 2017 Jun 19;79(6):1257-1265. Epub 2017 Apr 19.

Drug Development Department (DITEP), Gustave Roussy Cancer Centre, Université Paris-Saclay, 114 Rue Eduard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3303-zDOI Listing
June 2017

[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?]

Bull Cancer 2017 May 19;104(5):485-493. Epub 2017 Apr 19.

Université Paris-Saclay, Gustave-Roussy Cancer Centre, Drug Development Department (DITEP), 94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.03.008DOI Listing
May 2017

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Anticancer Drugs 2017 03;28(3):341-349

aGustave Roussy Cancer Centre, Paris-Saclay University, Drug Development Department (DITEP), Villejuif bHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite Cedex cHematology and Cellular Therapy Department, CIC INSERM 1415, University Hospital Centre, Tours, France dCancer Institute of New Jersey, New Brunswick, New Jersey, USA ePharmaMar, S.A., Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000457DOI Listing
March 2017

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Cancer Discov 2017 02;7(2):128-130

Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1439DOI Listing
February 2017

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Anticancer Drugs 2016 11;27(10):1021-7

aJules Bordet Institute, Brussels, Belgium bGustave Roussy, Paris-Saclay University, Drug Development Department (DITEP), Villejuif, France cPharma Mar, S.A., Avenida de los Reyes, 1, Polígono Industrial La Mina-Norte, 28770 Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000409DOI Listing
November 2016

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Eur J Cancer 2016 09 21;65:33-42. Epub 2016 Jul 21.

Université Paris-Saclay, Paris, France; Gustave Roussy, Université Paris-Saclay, Drug Development Department, Villejuif, F-94805, France; Gustave Roussy, Université Paris-Saclay, INSERM U981, Predictive Biomarkers and New Therapeutic Strategies in Oncology, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.05.031DOI Listing
September 2016

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

J Thorac Oncol 2016 Feb 18;11(2):e21-3. Epub 2015 Dec 18.

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.08.001DOI Listing
February 2016

Rationale for anti-OX40 cancer immunotherapy.

Eur J Cancer 2016 Jan 30;52:50-66. Epub 2015 Nov 30.

DITEP, Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France; INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.08.021DOI Listing
January 2016

Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.

Chin Clin Oncol 2015 Dec;4(4):48

IGustave Roussy, Université Paris-Saclay, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.12.06DOI Listing
December 2015

Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.

Bioorg Med Chem 2015 Jul 4;23(13):3175-82. Epub 2015 May 4.

Laboratory for Medicinal Chemistry (FFW), Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2015.04.068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461518PMC
July 2015

An in silico approach for modelling T-helper polarizing iNKT cell agonists.

PLoS One 2014 31;9(1):e87000. Epub 2014 Jan 31.

Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087000PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909045PMC
October 2014

Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells.

J Immunol 2013 Sep 29;191(5):2174-83. Epub 2013 Jul 29.

Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1300562DOI Listing
September 2013

Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.

J Immunol 2013 Sep 19;191(6):2916-25. Epub 2013 Aug 19.

Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1203134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817951PMC
September 2013

Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands.

Bioorg Med Chem 2012 Dec 12;20(24):7149-54. Epub 2012 Oct 12.

Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Gent, Belgium.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896120079
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2012.09.063DOI Listing
December 2012

Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.

PLoS One 2012 23;7(5):e37991. Epub 2012 May 23.

Division of Biology and Medicine, Department of Molecular Microbiology and Immunology and Graduate Program in Pathobiology, Brown University, Providence, Rhode Island, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0037991PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359346PMC
October 2012

Divergent synthetic approach to 6''-modified α-GalCer analogues.

Org Biomol Chem 2011 Dec 1;9(24):8413-21. Epub 2011 Nov 1.

Laboratory for Medicinal Chemistry (FFW), Faculty of Pharmaceutical Sciences, UGent, Harelbekestraat 72, B-9000 Gent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c1ob06235bDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246390PMC
December 2011

Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.

EMBO J 2011 Jun 6;30(11):2294-305. Epub 2011 May 6.

Department of Rheumatology, Faculty of Medicine and Health Sciences, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/emboj.2011.145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117654PMC
June 2011

Synthesis and evaluation of amino-modified alpha-GalCer analogues.

Org Lett 2010 Jul;12(13):2928-31

Laboratory for Medicinal Chemistry (FFW), Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ol100934zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903208PMC
July 2010

Invariant natural killer T cells in rheumatic disease: a joint dilemma.

Nat Rev Rheumatol 2010 Feb;6(2):90-8

Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital, 185 De Pintelaan, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2009.261DOI Listing
February 2010